US FDA Exploring Consortium To Develop Treatments For ‘Economically Infeasible’ Cancer Indications

The FDA could partner with industry, academia and advocacy groups to speed development of novel treatments for cancers that are not commercially viable.

drug development — The public-private consortium could represent a substantial expansion of the FDA's Project Catalyst. • Source: Shutterstock

The US Food and Drug Administration may create a public-private consortium to help develop treatments for cancer indications that are not commercially viable, another potential step into the drug development business that could raise questions from industry or Congress.

The idea is still in its early stages. Jeff Summers, associate director for translational sciences in the Center for Drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

New EU Filings

13 Aug 2025

• By Neena Brizmohun

Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight

13 Aug 2025

• By Manas Mishra

AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.